Enzymatica publishes prospectus
April 20 2016 - 8:54AM
This press release may not be
published or distributed, directly or indirectly, in or into the
United States, Australia, Japan, Canada, Hong Kong, New Zeeland,
Singapore or South Africa or any other jurisdiction where such
action is subject to legal restrictions.
Enzymatica announces today that
the prospectus for the rights issue, approved by the Extraordinary
General Meeting on April 14, has been approved by the Swedish
Financial Supervisory Authority and is now available of
Enzymatica's web site, www.enzymatica.com.
The prospectus including information and
instructions on how to participate in the rights issue has been
made available on Enzymatica's web site, www.enzymatica.se.
Shareholders whose holdings are directly
registered in Euroclear Sweden AB on the record date April 19, 2016
will receive a printed issue statement including an application
form. Shareholders whose holdings are in a nominee bank or other
nominee will not receive a printed issue statement. Subscription
and payment for new shares subscribed for through subscription
rights is made through the respective nominee in accordance with
the instructions from such nominee, or if the holdings are
registered with several nominees, from each nominee
respectively.
The subscription period runs from 21 April
to 6 May 2016. Those who hold shares in Enzymatica on the
record date will receive one (1) subscription right per share and
five (5) subscription rights entitle to subscribe for three (3) new
shares in the company at a price of SEK 2.18 per share. In
addition, shareholders and other investors are invited to subscribe
for shares without preferential right. The rights issue is fully
secured through guarantees and subscription commitments.
For
more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: fredrik.lindberg@enzymatica.com
Carl-Johan Wachtmeister, deputy communication
officer Enzymatica
Tel: 0701-88 50 21 | E-post:
carl-johan.wachtmeister@enzymatica.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical
device products against infectious-related diseases. Over a short
period the company has developed a unique oral spray for colds,
ColdZyme®, and launched it on six markets. The product has become
one of the leading articles for colds in Swedish pharmacies.
Enzymatica's strategy is to continue growing by strengthening its
position in existing markets and to expand to more geographical
markets through well-established partners. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North.
For more information, please visit
www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser
Bankaktiebolag.
Important
information
The information in this press release does not
contain or constitute an offer to acquire, subscribe or otherwise
trade in shares, subscription rights or other securities in
Enzymatica AB (publ). Any invitation to the persons concerned to
subscribe for shares in Enzymatica AB (publ) will only be made
through the prospectus that Enzymatica AB (publ) estimates to
publish on or about 20 April 2016.
This press release may not be
published or distributed, directly or indirectly in or into the
United States, Australia, Japan, Canada, Hong Kong, New Zeeland,
Singapore or South Africa or any other jurisdiction where such
action is wholly or partially subject to legal restrictions or
where such action would require additional prospectuses,
registrations or other actions in addition to what follows from
Swedish law. Nor may the information in this press release be
forwarded, reproduced or disclosed in such a manner that
contravenes such restrictions or would require such requirements.
Failure to comply with this instruction may result in a violation
of applicable securities laws.
No subscription rights, interim
shares or new shares have been registered, and will not be
registered, under the United States Securities Act of 1933
("Securities Act") or securities legislation in any other state or
other jurisdiction in the United States and may not be offered,
subscribed, sold or transferred, directly or indirectly within the
United States, other than pursuant to an exemption from the
registration requirements of the Securities Act and in accordance
with securities laws in relevant state or other jurisdiction in the
United States.
This press release may contain
forward-looking statements which reflect Enzymatica AB (publ):s
current view on future events and financial and operational
development. Words such as "intend", "expect", "anticipate", "may",
"believe", "plan", "estimate" and other expressions which imply
indications or predictions of future development or trends, and
which are not based on historical facts, are intended to identify
forward-looking statements. Forward-looking statements inherently
involve both known and unknown risks and uncertainties because they
depend on future events and circumstances. Forward-looking
statements do not guarantee future results or development and the
real outcome could differ materially from the forward-looking
statements.
Press Release (PDF)
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Enzymatica AB via Globenewswire
HUG#2005155
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024